Evidence map›Paper›PMID 10691912›Full record

ArticleClinical and experimental immunology2000

Autoimmunity to glutamic acid decarboxylase in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED).

P Klemetti, P Björses, T Tuomi, J Perheentupa, J Partanen, N Rautonen, A Hinkkanen, J Ilonen, O Vaarala

Open access · greenAbstract read
In one paragraph

Article in Clinical and experimental immunology, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Metabolomic signature of amino acids in plasma of patients with non-segmental Vitiligo.Metabolomics : Official journal of the Metabolomic Society · 2021
    Article
  4. Review
  5. GAD antibody-associated limbic encephalitis in a young woman with APECED.Endocrinology, diabetes & metabolism case reports · 2017
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 2 countries.

P KlemettiDepartment of Biochemistry, National Public Health Institute, Hospital for Children and Adolescents, University of Helsinki, Finland.
P Björses
T Tuomi
J Perheentupa
J Partanen
N Rautonen
A Hinkkanen
J Ilonen
O Vaarala
University of Helsinki · FIUniversity of Turku · FIDuPont (Finland) · FIFinnish Red Cross · FIHelsinki University Hospital · FIInstitute for Molecular Medicine Finland · FIPublic Health Institute · US

Funding

DEVELOPMENTAL STUDIES HYBRIDOMA BANKN01HD023144 · NICHD · JOHNS HOPKINS UNIVERSITY · PI AUGUST, J. THOMAS THOMAS · 1992 to 1996
–
NICHD NIH HHS N01-HD-2-3144
6 · The paper itself

Abstract

Antibodies to glutamic acid decarboxylase (GAD) occur frequently in patients with APECED, although clinical insulin-dependent diabetes mellitus (IDDM) is seen only in a subgroup of the patients. We studied the cellular immunity to GAD, antibodies to GAD and their association with the HLA DQB1 risk alleles for IDDM in patients with APECED. Proliferation responses to GAD were enhanced in the patients with APECED when compared with the control subjects (P = 0.004), but autoimmunity to GAD was not associated with IDDM in APECED. The levels of interferon-gamma (IFN-gamma) secreted by GAD-stimulated T cells were higher in the patients than in control subjects (P = 0. 001). A negative correlation (r = - 0.436, P = 0.03) existed between the antibody levels and the stimulation indices (SIs) to GAD. In 14 non-diabetic patients no difference in insulin secretion was observed in intravenous glucose tolerance test (IVGTT) between the patients with and without T cell reactivity to GAD. We conclude that cellular immunity to GAD detected as T cell proliferation response to GAD or IFN-gamma secretion by GAD-stimulated T cells was frequent in patients with APECED (69%) and was not restricted to the patients with clinically detectable beta-cell damage.

Indexed as

AdolescentAdultAutoantibodiesAutoimmunityChildDiabetes Mellitus, Type 1FemaleGlutamate DecarboxylaseHumansMaleMiddle AgedPolyendocrinopathies, AutoimmuneAutoantibodiesGlutamate Decarboxylase

Identifiers

PMID10691912
PMCPMC1905591
OpenAlexW2084611222

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.